Superworth

Madrigal Pharmaceuticals price to book ratio MDGL

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
19.2×
10-year median
7.8×
Against its 10-year history
78th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.5× to 195×
Peer median
9.2×

Madrigal Pharmaceuticals' price to book ratio is 19.2× as of Oct 23, 2026.

That is above its ten-year median of 7.8×, higher than on 78% of days in the last ten years.

Over that time it ranged from 1.5× in Nov 2016 to 195× in Jan 2024.

The median for 10 large drugmakers of a similar size is 9.2×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far19.2×16.4×23.9×
202521.7×8.2×21.7×
20248.8×5.1×195×
2023185×21.5×189×
2022102×4.1×128×
20216.2×4.8×9.1×
20205.9×2.2×6.8×
20193.3×2.8×4.5×
20183.3×3.0×34.1×
201721.1×3.1×21.9×
20164.6×0.4×5.1×
20150.8×0.7×7.2×
20143.4×3.4×30.5×
201323.3×4.9×24.0×
201217.1×6.3×28.8×
20119.4×4.2×9.8×

Against its peers

Companies in Drug Manufacturers - General nearest Madrigal Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
MDGLMadrigal Pharmaceuticals19.2×
BMRNBiomarin Pharmaceutical1.7×
CORTCorcept Therapeutics13.2×
PTGXProtagonist Therapeutics10.6×
TGTXTG Therapeutics13.7×
ALKSAlkermes plc.4.0×
JAZZJazz Pharmaceuticals2.9×
AMRXAmneal Pharmaceuticals197×
LGNDLigand Pharmaceuticals6.3×
KNSAKiniksa Pharmaceuticals International9.2×
INDVIndivior Pharmaceuticalsn/m
Peer median9.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Madrigal Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.